Below is the uncorrected machine-read text of this chapter, intended to provide our own search engines and external engines with highly rich, chapter-representative searchable text of each book. Because it is UNCORRECTED material, please consider the following text as a useful but insufficient proxy for the authoritative book pages.
10 Manganese SUMMARY Manganese is involved in the formation of bone and in amino acid, lipid, and carbohydrate metabolism. There were insufficient data to set an Estimated Average Requirement (EAR) for manga- nese. An Adequate Intake (AI) was set based on median intakes reported from the Food and Drug Administration Total Diet Study. The AI for adult men and women is 2.3 and 1.8 mg/day, respectively. A Tolerable Upper Intake Level (UL) of 11 mg/day was set for adults based on a no-observed-adverse-effect level for Western diets. BACKGROUND INFORMATION Function Manganese is an essential nutrient involved in the formation of bone and in amino acid, cholesterol, and carbohydrate metabolism. Manganese metalloenzymes include arginase, glutamine synthetase, phosphoenolpyruvate decarboxylase, and manganese superoxide dismutase. Glycosyltransferases and xylosyltransferases, which are important in proteoglycan synthesis and thus bone formation, are sensitive to manganese status in animals. Several other manganese- activated enzymes, including pyruvate carboxylase, can also be acti- vated by other ions, such as magnesium. 394
MANGANESE 395 Physiology of Absorption, Metabolism, and Excretion Only a small percentage of dietary manganese is absorbed. Absorbed manganese is excreted very rapidly into the gut via bile (Britton and Cotzias, 1966; Davis et al., 1993). Most estimates of absorption have been based on whole body retention curves at approximately 10 to 20 days after dosing with 54Mn. Using this method, Finley and coworkers (1994) estimated absorption from a test meal containing 1 mg manganese to be 1.35 Â± 0.51 percent (standard deviation [SD]) for men and 3.55 Â± 2.11 percent (SD) for women. From a test meal containing 0.3 to 0.34 mg of manganese, Davidsson and coworkers (1988) found the retention of 54Mn to be 5.0 Â± 3.1 percent (SD) 10 days after administration to young adult women. Turnover of orally administered 54Mn was much more rapid after oral administration than after intravenous administration (Davidsson et al., 1989b; Sandstrom et al., 1986). Furthermore, absorption of manganese after 30 weeks of supplementation was 30 to 50 percent lower than had been observed in nonsupplemented subjects (Sandstrom et al., 1990). Some studies indicate that man- ganese is absorbed through an active transport mechanism (Garcia- Aranda et al., 1983), but passive diffusion has been suggested on the basis of studies indicating that manganese absorption occurs by a nonsaturable process (Bell et al., 1989). Manganese is taken up from the blood by the liver and transported to extrahepatic tissues by transferrin (Davidsson et al., 1989c) and possibly Î±2-macroglobulin (Rabin et al., 1993) and albumin (Davis et al., 1992). Manganese inhibited iron absorption, both from a solu- tion and from a hamburger meal (Rossander-Hulten et al., 1991). 54Mn has a longer half-life in men than in women (Finley et al., 1994). A significant negative association between manganese absorption and plasma ferritin concentrations has recently been reported (Finley, 1999). Serum ferritin concentrations differ in men and women (Appendix Table G-3); therefore, a major factor in establishing manganese requirements may be gender. Manganese is excreted primarily in feces. Urinary excretion of manganese is low and has not been found to be sensitive to dietary manganese intake (Davis and Greger, 1992). Urinary excretion in a balance study of five healthy men varied from 0.04 to 0.14 percent of their intake, and absolute amounts in the urine decreased dur- ing the depletion phases of the study (Freeland-Graves et al., 1988). Therefore, potential risk for manganese toxicity is highest when bile excretion is low, such as in the neonate or in liver disease (Hauser et al., 1994). Plasma manganese concentrations can be-
396 DIETARY REFERENCE INTAKES come elevated in infants with choleostatic liver disease given sup- plemental manganese in total parenteral nutrition solutions (Kelly, 1998). It is not certain at what age human infants can maintain manganese homeostasis. Neonatal mice were unable to maintain manganese homeostasis until 17 to 18 days of age (Fechter, 1999). Clinical Effects of Inadequate Intake Manganese deficiency has been observed in various species of animals with the signs of deficiency, including impaired growth, impaired reproductive function, impaired glucose tolerance, and alterations in carbohydrate and lipid metabolism. Furthermore, manganese deficiency interferes with normal skeletal development in various animal species (Freeland-Graves, 1994; Hurley and Keen, 1987; Keen et al., 1994). Although a manganese deficiency may contribute to one or more clinical symptoms, a clinical deficiency has not been clearly associated with poor dietary intakes of healthy individuals. One man was depleted of vitamin K and inadvertently of manganese when fed a diet containing only 0.34 mg/day of man- ganese for 6.5 months. Symptoms included hypocholesterolemia, scaly dermatitis, hair depigmentation, and reduced vitamin K- dependent clotting proteins. Symptoms were not reversed with vita- min K supplementation but gradually disappeared after the study ended (Doisy, 1973). In a manganese depletion study, seven young men were fed a purified diet containing 0.01 mg/day of manganese for 10 days and 0.11 mg/day of manganese for 30 days after a 3-week baseline period when they consumed 2.59 mg/day (Friedman et al., 1987). After 35 days, five of the seven subjects developed a finely scaling, minimally erythematous rash that primarily covered the upper torso and was diagnosed as Miliaria crystallina. After two days of repletion, the blisters disappeared and the affected areas became scaly and then cleared. Plasma cholesterol concentrations declined during the deple- tion period, perhaps because manganese is required at several sites in the biosynthetic pathway of cholesterol (Krishna et al., 1966). Decreased plasma manganese concentrations have been reported in osteoporotic women. Furthermore, bone mineral density was im- proved when trace minerals, including manganese, were included with calcium in their diets or supplements (Freeland-Graves and Turnlund, 1996; Strause and Saltman, 1987; Strause et al., 1986, 1987). Penland and Johnson (1993) reported that diets containing only 1 mg/day of manganese altered mood and increased pain during the premenstrual phase of the estrous cycle in young women.
MANGANESE 397 SELECTION OF INDICATORS FOR ESTIMATING THE REQUIREMENT FOR MANGANESE Balance and Depletion Studies Interindividual variations in manganese retention can be large (Davidsson et al., 1989b). Ten days after giving 54Mn in an infant formula to 14 healthy men and women, manganese retention ranged from 0.6 to 9.2 percent. Mean retention in these subjects was 2.9 Â± 1.8 percent (standard deviation [SD]). Intraindividual variation was not as large, and retention values of 2.3 Â± 1.1, 3.3 Â± 3.1, and 2.4 Â± 1.4 percent (SD) were observed for three repeated doses in six subjects (Davidsson et al., 1989b). In one study, seven healthy men, aged 19 to 22 years, were fed a purified low-protein diet containing 0.01 mg/day of manganese for days 1 to 10, followed by a protein-adequate diet containing 0.11 mg/day of manganese until day 39. Using a factorial method, the authors estimated that the minimum requirement for manganese was 0.74 mg/day and estimated on the basis of the percentage of manganese retention that 2.11 mg/day would be required (Friedman et al., 1987). Subsequently, five young men were fed a diet of ordinary foods (1.21 mg/day of manganese) supplemented with manganese sulfate or placebo at the evening meal to create five different levels of manganese intake (Freeland-Graves et al., 1988). Total manga- nese intakes were 2.89 mg/day for days 1 to 21, 2.06 mg/day for days 22 to 42, 1.21 mg/day for days 43 to 80, 3.79 mg/day for days 81 to 91 (repletion), and 2.65 mg/day for days 92 to 105. The mean manganese balances for the corresponding days were 0.083, -0.018, -0.088, +0.657, and +0.0136 mg/day, respectively. An 8-week balance study conducted by Hunt and coworkers (1998) showed that women, aged 20 to 42 years, were in slightly positive mean balance when consuming 2.5 mg/day of manganese. Some adolescent girls were observed to be in negative or slightly positive balance when consuming 3 mg/day of manganese (Greger et al., 1978a, 1978b). Balance studies are problematic for investigation of manganese requirement because of the rapid excretion of manganese into bile and because manganese balances during short- and moderate-term studies do not appear to be proportional to manganese intakes (Greger, 1998, 1999). For these reasons, a number of studies have achieved balance over a wide range of manganese intakes (Table 10-1). Therefore, balance data were not used for estimating an aver- age requirement for manganese.
398 DIETARY REFERENCE INTAKES TABLE 10-1 Manganese Balance Studies in Adults Balance Data Reference Study Group Duration Diet (mg/d) (mg/d) McLeod and 4 women, 27 d 2.78 0.32 Robinson, 1972 19â22 y Spencer et al., 9 men, 18â24 d 2.23 â0.28 1979 41â63 y Johnson et al., 8 men, 40 d 3.28 â10 to â21 1982 21â28 y Patterson et al., 28 men and 7d 2.8 â0.16 1984 women, 3.0 â0.16 20â53 y 2.9 â0.21 3.2 â0.12 Behall et al., 11 men, 4 wk 5.5 â0.4 1987 23â62 y Friedman et al., 7 men, 39 d 0.11 â0.02 1987 29â22 y 5d 1.53 0.84 5d 2.55 1.02 Hallfrisch et al., 20 men, 1 wk 5.35 1.65 1987 23â56 y duplicate 19 women, food 6.14 3.19 21â48 y record Freeland-Graves 5 young 21 d 2.89 0.083 et al., 1988 men 20 d 2.06 0.018 37 d 1.21 â0.088 10 d 3.79 0.657 13 d 2.65 0.0136 Holbrook et al., 19 men, 7 wk 2.4 to 2.9 â0.6 to 0.4 1989 21â57 y Johnson and 14 women, 39 d 5.66 0.1 Lykken, 1991 27 y 5.52 0.3 0.95 â0.01 0.94 0.06 0.16 0.46 continued
MANGANESE 399 TABLE 10-1 Continued Balance Data Reference Study Group Duration Diet (mg/d) (mg/d) Ivaturi and 24 men and 14 d 3.21 0.3 Kies, 1992 women 3.92 0.3 3.13 â0.2 2.64 0.23 3.13 0.51 3.15 0.32 Finley et al., 20 men and 14 d 5.43 (men) 0.27 1994 20 women, 4.01 (women) â0.12 18â40 y Hunt et al., 21 women, 8 wk 2.5 (non- 0.1 1998 20â42 y vegetarian) 5.9 (lacto-ovo- 0.6 vegetarian) Serum and Plasma Manganese Concentration Several studies reported that serum or plasma manganese con- centrations respond to dietary intake. Serum manganese concentra- tion of women consuming 1.7 mg/day of manganese was lower than that of women ingesting 15 mg/day of supplemental manganese for more than 20 days (Davis and Greger, 1992). In a depletion trial (Freeland-Graves and Turnlund, 1996), plasma manganese concen- tration was 1.28 Âµg/L at baseline. Concentrations were significantly lower during the second (0.95 Âµg/L) and third (0.80 Âµg/L) dietary periods with manganese intakes of 2.06 and 1.21 mg/day, respec- tively. Values increased significantly to 1.11 Â± 0.35 Âµg/L when the diet was repleted with 3.8 mg/day of manganese. During the final dietary periods, manganese intake was 2.65 mg/day, and plasma manganese concentration was 0.97 Â± 0.33 Âµg/L. Plasma manganese concentration was not significantly correlated with manganese in- take levels. In a study in which 10 men consumed 0.52 to 5.33 mg/day of manganese, serum manganese concentration did not respond to varied dietary intakes (Greger et al., 1990). Individual serum man- ganese concentrations varied from 0.4 to 2.12 Âµg/L with an average of 1.04 Âµg/L. However, serum manganese concentrations of four of five subjects who consumed 15 mg of chelated manganese as a
400 DIETARY REFERENCE INTAKES dietary supplement for 5 days were 27 nmol/L (1.48 Âµg/L), whereas unsupplemented control subjects had a mean serum concentration of 20 nmol/L (1.1 Âµg/L). Serum or plasma manganese concentrations appear to be some- what sensitive to large variations in manganese intake, but longer studies are needed to evaluate the usefulness of serum manganese concentrations as indicators of manganese status. Blood Manganese Concentration An advantage of whole blood manganese concentration over plasma or serum manganese concentration as an indicator is that slight hemolysis of samples can markedly increase plasma or serum manganese concentrations. Whole blood manganese seems to be extremely variable, however, which may preclude it as a viable status indicator. In a manganese depletion study, manganese concentra- tion in whole blood was 9.57 Âµg/L (range 5.40 to 17.1) at the end of the baseline period and 6.01 Âµg/L (4.43 to 7.57) at the end of the 39-day depletion period, but there was not a significant difference between these values (Friedman et al., 1987). With 10 days of man- ganese repletion, whole blood manganese concentration increased to 6.99 Âµg/L (3.93 to 18.3). Urinary Manganese Urinary manganese is responsive to severe manganese depletion. After a patient spent 7 days on a depletion diet containing 0.11 mg/ day of manganese, the patientâs urinary manganese excretion sig- nificantly decreased from 8.64 to 2.45 Âµg/day, and it continued to decrease to as low as 0.39 Âµg/day after 35 days (Friedman et al., 1987). In a second manganese depletion trial, urinary manganese decreased significantly as manganese intake decreased from 2.9 to 2.1 to 1.2 mg/day (Freeland-Graves et al., 1988). After repletion with 3.8 mg/day, urinary manganese excretion increased then de- creased following an intake of 2.65 mg/day. In contrast to the above findings, when ten men consumed 0.52 to 5.33 mg/day, urinary excretion of manganese did not correspond with manganese intake (Greger et al., 1990). Urinary losses of manganese averaged 0.38 Âµg/g creatinine. Also, Davis and Greger (1992) could not demonstrate that women given 15 mg/day of man- ganese during a 125-day supplementation period excreted more manganese in urine than women consuming 1.7 mg/day in food. Thus, there is controversy on the use of urinary manganese for
MANGANESE 401 assessment of status when typical amounts of manganese are consumed. Arginase Activity Arginase is depressed in the livers of manganese-deficient rats (Paynter, 1980). Brock and coworkers (1994) noted that manganese- deficient rats also had depressed plasma urea and elevated plasma ammonia concentrations. Arginase is affected by a variety of factors, however, including high protein diet and liver disease (Morris, 1992). Manganese-Superoxide Dismutase Activity Manganese-deficient animals have low manganese-superoxide dis- mutase (MnSOD) activity (Davis et al., 1992; Malecki et al., 1994; Zidenberg-Cherr et al., 1983). Davis and Greger (1992) demonstrated that lymphocyte MnSOD activity was elevated in 47 women supple- mented with 15 mg/day of manganese for more than 90 days. How- ever, other factors like ethanol (Dreosti et al., 1982) and dietary polyunsaturated fatty acids (Davis et al., 1990) may affect MnSOD activity. A fairly large blood sample is required to measure lympho- cyte MnSOD. FACTORS AFFECTING THE MANGANESE REQUIREMENT Bioavailability Prior intakes of manganese and of other elements, such as cal- cium, iron, and phosphorus, have been found by some investigators to affect manganese retention (Freeland-Graves and Lin, 1991; Greger, 1998; Lutz et al., 1993). Adding calcium to human milk significantly reduced the absorption of 54Mn from 4.9 to 3.0 per- cent (Davidsson et al., 1991). Low ferritin concentrations are associ- ated with increased manganese absorption, therefore having a gender effect on manganese bioavailability (Finley, 1999). Sandstrom and coworkers (1990) gave a multimineral supplement that included 18 mg of iron, 15 mg of zinc, and 2.5 mg of manga- nese for a minimum of 30 weeks. Neither whole blood manganese concentration nor superoxide dismutase activity was increased sig- nificantly from baseline with supplementation. Seven healthy vol- unteers subsequently consumed a tracer dose containing 54Mn, 75Se, and 65Zn. Manganese absorption was only 1 percent of the oral dose. Sandstrom and coworkers (1987) reported a higher rate of
402 DIETARY REFERENCE INTAKES absorption from this dose in subjects without prior consumption of a supplement, but high interindividual variability of manganese absorption and other potential confounders would require a study specifically designed to test the effect of prior supplementation on 54Mn absorption. Davidsson and coworkers (1995) administered 54Mn in either a soy-based infant formula or a similar dephytinized formula to eight men and women. The geometric mean manganese absorption was 0.7 percent for the native formula and 1.6 percent for the dephytinized formula. Therefore, the presence of phytate reduced the efficiency of absorption of manganese. Johnson and colleagues (1991) reported that manganese absorp- tion did not significantly differ between plant foods that were extrinsically or intrinsically labeled with 54MnCl2. Absorption of 54Mn from a meal, extrinsically labeled with 54MnCl , was signifi- 2 cantly higher (8.9 percent) than the absorption of 54Mn from lettuce (5.2 percent), spinach (3.8 percent), wheat (2.2 percent), or sunflower seeds (1.7 percent). Absorption of 54MnCl2 did not differ whether the dose was 0.53 or 1.24 mg (7 to 10 percent). Gender Finley and coworkers (1994) reported that men absorbed signifi- cantly less manganese than women and that this difference may be related to iron status. A subsequent study specifically demonstrated that high ferritin concentrations were associated with reduced 54Mn absorption (Finley, 1999). Serum ferritin concentrations are higher in men (Appendix Table G-3) and therefore may affect, in part, the lower bioavailability of manganese observed in men. FINDINGS BY LIFE STAGE AND GENDER GROUP Infants Ages 0 through 12 Months Method Used to Set the Adequate Intake No functional criteria of manganese status have been demonstrated that reflect response to dietary intake in infants. Thus, recommended intakes of manganese are based on an Adequate Intake (AI) that reflects the observed mean manganese intake of infants principally fed human milk.
MANGANESE 403 Ages 0 through 6 Months. On the basis of the method described in Chapter 2 and the manganese concentration of milk produced by well-nourished mothers, the AI reflects the observed mean manga- nese intake of infants exclusively fed human milk during their first 6 months. There are no reports of full-term infants exclusively and freely fed human milk by U.S. or Canadian mothers who manifested any signs of manganese deficiency (Davidsson et al., 1989a). Mean manganese concentrations of human milk at 1 month were approx- imately 4.0 Âµg/L (Aquilio et al., 1996; Casey et al., 1985, 1989) and declined to 1.87 Âµg/L by 3 months postpartum (Casey et al., 1989) (Table 10-2). Total manganese secretion in human milk averaged 1.9 Âµg/day over the first 3 months and 1.6 Âµg/day over the second 3 months (Casey et al., 1989). Based on the above data, the AI is set according to average milk volume consumption (0.78 L/day) Ã the average manganese concentration in human milk (3.5 Âµg/L), or 3 Âµg/day, after rounding (see Chapter 2). TABLE 10-2 Manganese Concentration in Human Milk Estimated Milk Manganese Stage of Concentration Intake of Reference Study Group Lactation (Âµg/L) Infants (Âµg/d) a Stastny et al., 24 women 4 wk 6.6 5.2 1984 8 wk 4.8 3.7 12 wk 3.5 2.7 Casey et al., 11 women, 8d 3.7 2.9 1985 26â39 y 14 d 3.8 2.9 21 d 3.2 2.5 28 d 4.1 3.2 Casey et al., 22 women 1 mo 3.5 2.7 1989 3 mo 1.87 1.5 Anderson, 10 women Up to 6.97 5.4 1992 5 mo Aquilio et al., 14 women 2â6 d 3.9 3.0 1996 12â16 d 3.9 3.0 21 d 4.1 3.2 NOTE: Maternal intakes were not reported in these studies. a Manganese intake based on reported data or concentration (Âµg/L) Ã 0.78 L/day.
404 DIETARY REFERENCE INTAKES Ages 7 through 12 Months. With the introduction of complementary foods, it has been estimated that the average consumption of man- ganese by 6- and 12-month-old infants is 71 and 80 Âµg/kg, respec- tively (Gibson and De Wolfe, 1980). Based on reference weights of 7 and 9 kg for these two ages, the total manganese intake would be 500 and 720 Âµg/day. Using the reference body weight method described in Chapter 2 to extrapolate from adults, the average intake is 567 Âµg/day. Based on these two approaches, the AI is set at 600 Âµg/day for older infants. The AI for older infants is markedly greater than the AI for younger infants because the concentration of manganese is higher in foods than in human milk. Manganese AI Summary, Ages 0 through 12 Months AI for Infants 0â6 months 0.003 mg/day (3 Âµg/day) of manganese 7â12 months 0.6 mg/day of manganese Special Considerations The manganese concentration in cow milk has been reported to range from 20 to 50 Âµg/L (Lonnerdal et al., 1981), which is signifi- cantly greater than the concentration in human milk (Table 10-2). Manganese is partly present in the fat globule membrane in cow milk (Murthy, 1974). Davidsson and coworkers (1989a) reported that the fractional manganese absorption from human milk (8.2 percent) was higher than from soy formula (0.7 percent) and whey- preponderant cowâs milk formula (3.1 percent). Children and Adolescents Ages 1 through 18 Years Method Used to Set the Adequate Intake Ages 1 through 3 Years. There are insufficient data to set an Estimated Average Requirement (EAR) for manganese for children ages 1 through 3 years. Therefore, median intake data were used to set the AI. Data from the Food and Drug Administration Total Diet Study indicate a median intake of 1.22 mg/day of manganese for children aged 1 through 3 years (Appendix Table E-6). Ages 4 through 13 Years. There have been a few manganese balance studies with children and all are subject to the caveats previously
MANGANESE 405 discussed. Therefore, they were not considered in setting an EAR. The Total Diet Study indicates a median intake of 1.48 mg/day for children aged 4 through 8 years. Median intakes for girls and boys, ages 9 through 13 years, were 1.57 and 1.91 mg/day, respectively (Appendix Table E-6). Ages 14 through 18 Years. A few studies have been conducted to assess the manganese requirement in adolescent girls. Adolescent girls were observed to be in negative (Greger et al., 1978a) or slight positive balance (Greger et al., 1978b) when consuming 3 mg/day of manganese. These varied findings in adolescent girls may be due to a variation in iron status given that a significant negative associa- tion between manganese absorption and plasma ferritin concentra- tions has been reported recently (Finley, 1999). Because of the limitations of balance data, as previously discussed, these data were not used to set the EAR. The Total Diet Study indicates that the median manganese intake for adolescent girls and boys was 1.55 and 2.17 mg/day, respectively (Appendix Table E-6). Because clear associations between low man- ganese intake and clinical symptoms of a manganese deficiency have not been observed, the AI is based on median intakes for each of the age groups. Manganese AI Summary, Ages 1 through 18 Years AI for Children 1â3 years 1.2 mg/day of manganese 4â8 years 1.5 mg/day of manganese AI for Boys 9â13 years 1.9 mg/day of manganese 14â18 years 2.2 mg/day of manganese AI for Girls 9â13 years 1.6 mg/day of manganese 14â18 years 1.6 mg/day of manganese Adults Ages 19 Years and Older Method Used to Set the Adequate Intake Because a wide range of manganese intakes can result in manga- nese balance, balance data could not be used to set an EAR. Several
406 DIETARY REFERENCE INTAKES balance studies have collectively concluded that manganese balance can be achieved at around 2.1 to 2.5 mg/day (Freeland-Graves et al., 1988; Friedman et al., 1987; Hunt et al., 1998). Based on a coefficient of variation of 10 percent, balance data would yield a Recommended Dietary Allowance (RDA) of 2.5 to 3 mg/day. Based on the Total Diet Study (Appendix Table E-6), the median manga- nese intake for men was 2.1 to 2.3 mg/day, and the median intake for women was 1.6 to 1.8 mg/day. Because overt symptoms of a manganese deficiency are not apparent in North America, an RDA based on balance data most likely overestimates the requirement for most North American individuals. Therefore, intake data are used to set an AI for manganese. Because dietary intake assessment methods tend to underestimate the actual daily intake of foods, the highest intake value reported for the four adult age groups was used to set the AI for each gender. Manganese AI Summary, Ages 19 Years and Older AI for Men 19â30 years 2.3 mg/day of manganese 31â50 years 2.3 mg/day of manganese 51â70 years 2.3 mg/day of manganese > 70 years 2.3 mg/day of manganese AI for Women 19â30 years 1.8 mg/day of manganese 31â50 years 1.8 mg/day of manganese 51â70 years 1.8 mg/day of manganese > 70 years 1.8 mg/day of manganese Pregnancy Method Used to Set the Adequate Intake There are limited data, such as fetal manganese concentration, on which to base an EAR specific to pregnancy. Casey and Robinson (1978) reported that manganese concentrations in fetal tissues ranged from 0.35 to 9.27 Âµg/g dry weight. In animals, manganese deficiency in utero produces ataxia and impaired otolith develop- ment, but these defects have not been reported in humans. The additional manganese requirement during pregnancy is determined by extrapolating up from adolescent girls and adult women as described in Chapter 2. Carmichael and coworkers (1997)
MANGANESE 407 reported that the median weight gain of 7,002 women who had good pregnancy outcomes was 16 kg. No consistent relationship between maternal age and weight gain was observed in six studies of U.S. women (IOM, 1990). Therefore, 16 kg is added to the refer- ence weight for adolescent girls and adult women for extrapolation. The AI for pregnant adolescent girls and women is 2 mg/day after rounding. This value is similar to dietary manganese intake data obtained from the Total Diet Study (Appendix Table E-6). Manganese AI Summary, Pregnancy AI for Pregnancy 14â18 years 2 mg/day of manganese 19â30 years 2 mg/day of manganese 31â50 years 2 mg/day of manganese Lactation Method Used to Set the Adequate Intake There are no data available that directly assess the manganese requirement in lactating women. Approximately 3 Âµg/day of man- ganese is secreted in human milk. Even though the requirement during lactation does not appear to be greater than the require- ment for nonlactating women, the median intake of 2.56 mg/day of manganese is greater during lactation (Appendix Table E-6). Be- cause a manganese deficiency has not been observed in North American lactating women, the AI is based on the median intake and rounding to 2.6 mg/day. Manganese AI Summary, Lactation AI for Lactation 14â18 years 2.6 mg/day of manganese 19â30 years 2.6 mg/day of manganese 31â50 years 2.6 mg/day of manganese INTAKE OF MANGANESE Food Sources Based on the Total Diet Study, grain products contributed 37 percent of dietary manganese, while beverages (tea) and vegetables
408 DIETARY REFERENCE INTAKES contributed 20 and 18 percent, respectively, to the adult male diet (Pennington and Young, 1991). Dietary Intake Patterson and coworkers (1984) analyzed manganese intakes for 7 days during each of the four seasons for 28 healthy adults living at home. The mean nutrient density for all subjects was 1.6 mg/1,000 kcal. Mean manganese intake for men was 3.4 mg/day and for wom- en, 2.7 mg/day. Greger and coworkers (1990) analyzed duplicate portions of all foods and beverages consumed for ten men. With unrestricted diets, the mean manganese intake was 2.8 mg/day. Daily intakes of manganese throughout the study varied from 0.52 to 5.33 mg/day. Based on the Total Diet Study (Appendix Table E-6), median intakes for women and men ranged from 1.6 to 2.3 mg/day. In various surveys, average manganese intakes of adults eating Western-type and vegetarian diets ranged from 0.7 to 10.9 mg/day (Freeland-Graves, 1994; Gibson, 1994). Intake from Supplements Approximately 12 percent of the adult U.S. population consumed supplements containing manganese in 1986 (Moss et al., 1989; Table 2-2). Based on the Third National Health and Nutrition Examina- tion Survey data, the median supplemental intake of manganese by adults who take supplements was approximately 2.4 mg/day, an amount similar to the dietary intake of manganese (Appendix Table C-20). TOLERABLE UPPER INTAKE LEVELS The Tolerable Upper Intake Level (UL) is the highest level of daily nutrient intake that is likely to pose no risk of adverse health effects in almost all individuals. Although members of the general population should be advised not to exceed the UL routinely, in- take above the UL may be appropriate for investigation within well- controlled clinical trials. Clinical trials of doses above the UL should not be discouraged, as long as subjects participating in these trials have signed informed consent documents regarding possible toxic- ity and as long as these trials employ appropriate safety monitoring of trial subjects. In addition, the UL is not meant to apply to indi- viduals who are receiving manganese under medical supervision.
MANGANESE 409 Hazard Identification Adverse Effects Manganese toxicity in humans is a well-recognized occupational hazard for people who inhale manganese dust. The most promi- nent effect is central nervous system pathology, especially in the extra-pyramidal motor system. The lesions and symptoms are simi- lar to those of Parkinsonâs disease (Barceloux, 1999; Keen et al., 1994). Manganese is probably transported into the brain via trans- ferrin (Aschner et al., 1999). These authors hypothesize that the greater vulnerability of the extrapyramidal system (globus pallidus and substantia nigra) for manganese accumulation could be due to the fact that these are areas that are efferent to areas of high trans- ferrin receptor density. These same efferent areas are also regions of high iron content. Neurotoxicity of orally ingested manganese at relatively low doses is more controversial. However, several lines of evidence suggest this possibility. The data on manganese neurotoxicity are reviewed below. Elevated Blood Manganese and Neurotoxicity. People with chronic liver disease have neurological pathology and behavioral signs of manga- nese neurotoxicity, probably because elimination of manganese in bile is impaired (Butterworth et al., 1995; Hauser et al., 1994; Spahr et al., 1996). This impairment results in higher circulating concen- trations of manganese, which then has access to the brain via trans- ferrin. Hauser and coworkers (1994) reported whole blood manga- nese concentrations of 18.8 to 45 Âµg/L in three patients with chronic liver disease, as compared to a normal range of 4.2 to 14.3 Âµg/L. Spahr and coworkers (1996) reported blood manganese con- centrations of 124.7 nmol/L (6.85 Âµg/L) in control subjects versus 331.4 nmol/L (18.2 Âµg/L) in patients with cirrhosis. High concen- trations of circulating manganese as a result of total parenteral nutrition have also been associated with manganese toxicity (Keen et al., 1999). Davis and Greger (1992) reported that women who ingested 15 mg/day of supplemental manganese had serum manga- nese concentrations that increased gradually throughout the 125- day study; significant differences were reported after 25 days of sup- plementation. Neurotoxicity in Laboratory Animals. High subchronic or chronic doses of manganese given to animals in food or water result in
410 DIETARY REFERENCE INTAKES central nervous system pathology and behavioral changes, although these changes are not necessarily identical to those seen in humans. A review by Newland (1999) suggests that manganese toxicity occurs at progressively lower doses when manganese is administered in food, in water, or by injection, respectively. Differences in toxic potency by route of administration may be an order of magnitude or more. The lowest dose study of manganese administered in food identified by Newland (1999) was by Komura and Sakamoto (1992). They fed male mice diets high in manganese (2 g/kg food) for 12 months (either as MnCl2, manganese acetate, MnCO3, or MnO2). Thus, a 30-gram mouse eating 4 g/day of food would have ingested about 266 mg/kg/day of manganese. Changes in brain regional biogenic amines and decreases in locomotor activity were observed, but changes were somewhat different for each salt. In general, man- ganese dioxide was found to be more toxic than other forms, and manganese chloride was least toxic. Several studies have examined neurotoxic effects of manganese in drinking water or administered by gavage. The two lowest dose studies are reviewed here. Bonilla (1984) gave male rats 0.1 or 5.0 mg/mL of manganese in drinking water for 8 months and mea- sured locomotor activity throughout this period. A significant in- crease in activity during the first month was found at both doses. Activity returned to normal for months 2 through 6, but in the seventh and eighth months, activity was less than that of control subjects in both groups. In a related study, Bonilla and Prasad (1984) gave rats 0.1 or 1.0 mg/L of manganese in drinking water for 8 months. They observed decreases of norepinephrine in striatum and pons of rats treated with the lower dose. Increases in the dopamine metabolite dihydroxyphenylacetic acid were found in striatum and hypothalamus at both doses. Homovanillic acid (another dopamine metabolite) decreased in striatum of the lower dose group. Changes in serotonin and its metabolite, 5-hydroxyindole acetic acid, were seen in some brain regions in the high dose group. As with the Komura and Sakamoto (1992) study, the actual doses of manganese in this study can only be approximated. Assuming that a 300 g rat ingests about 30 mL/day of water, then the daily dose of manga- nese in this study was about 10 mg/kg/day. Senturk and Oner (1996) exposed rats to 0.357 to 0.714 mg/kg/ day of manganese (as MnCl2) by gavage in distilled water for 39 days. Manganese levels in brain regions were elevated, and learning in a T-maze task was retarded. The learning impairment was asso- ciated with hypercholesterolemia, and the impairment was not seen
MANGANESE 411 when rats were co-administered mevilonin (a cholesterol biosynthesis inhibitor). The doses used in this study were very low. While no animal data exist showing that the neonate exhibits neurotoxic effects at lower doses of manganese than do adults, effects could be more severe in the developing brain. Pappas and colleagues (1997) exposed dams and litters to 2 or 10 mg/mL of manganese (as MnCl2) in drinking water from conception until postnatal day 20. Thinning of the cerebral cortex was observed in neonates exposed to both low and high doses. Keen and colleagues (1994) and Fechter (1999) suggested that the developing neonatal brain of animals may be more sensitive to high intakes of manganese. This sensitivity could be due to the greater expression of transferrin receptors in developing neurons or to an immature liver bile elimination system (Cotzias et al., 1976). Transfer of manganese to the fetus appears to be limited by the placenta (Fechter, 1999); therefore, the lack of development of manganese transport and elimination mechanisms is probably in- significant in the fetus. Ecological Studies in Humans. There is some indication that high manganese intake in drinking water is associated with neuromotor deficits similar to Parkinsonâs disease. Kondakis and coworkers (1989) studied people 50 years of age or older in three villages in Greece exposed to 3.6 to 14.6 Âµg/L of manganese in drinking water (n = 62), 81.6 to 252.6 Âµg/L (n = 49), or 1,800 to 2,300 Âµg/L (n = 77). People drinking the water with the highest concentration of manga- nese had signs and symptoms of motor deficits. Kawamura and coworkers (1941) reported severe neurological symptoms in 25 people who drank water contaminated with manganese from dry cell batteries for 2 to 3 months. The concentration of manganese in the water was between 14 and 28 mg/L. Vieregge and coworkers (1995) found no evidence of toxicity in people living in northern Germany (mean age of 57.5 years) drinking water with a manganese concen- tration between 300 and 2,160 Âµg/L (n = 41); they were compared with people drinking water with less than 50 Âµg/L of manganese. None of these studies measured dietary intakes of manganese, and so total intake is not known. However, it is possible that manga- nese in drinking water is more bioavailable than manganese in food (Velazquez and Du, 1994), and it is also possible that manganese in drinking water could be more toxic in people who already consume large amounts of dietary manganese from diets high in plant prod- ucts.
412 DIETARY REFERENCE INTAKES Summary Elevated blood manganese concentrations and neurotoxicity were selected as the critical adverse effects on which to base a UL for manganese. The totality of evidence in animals and humans sup- ports a causal association. Dose-Response Assessment Adults Data Selection. Human data, even if sparse, provide a better basis for determination of a UL than animal data. The low-dose animal studies do not establish a no-observed-adverse-effect level (NOAEL). Also, in the animal studies in which manganese was administered in food or water (Bonilla and Prasad, 1984; Komura and Sakamoto, 1992), only approximate doses or average doses can be established. A conservative approach was followed in order to protect against manganese neurotoxicity. Identification of NOAEL and Lowest-Observed-Adverse-Effect Level (LOAEL). A NOAEL of 11 mg/day of manganese from food was identified based on the data presented by Greger (1999). Greger (1999) re- viewed information indicating that people eating Western-type and vegetarian diets may have intakes as high as 10.9 mg/day of manga- nese. Schroeder and coworkers (1966) reported that a manganese- rich vegetarian diet could contain 13 to 20 mg/day of manganese. Because no adverse effects due to manganese intake have been noted, at least in people consuming Western diets, 11 mg/day is a reasonable NOAEL from food. A LOAEL of 15 mg/day can be iden- tified on the basis of an earlier study by Davis and Greger (1992). At this dose, there were significant increases in serum manganese con- centrations after 25 days of supplementation and in lymphocyte manganese-dependent superoxide dismutase activity after 90 days of supplementation. Uncertainty Assessment. Because of the lack of evidence of human toxicity from doses less than 11 mg/day of manganese from food, an uncertainty factor (UF) of 1.0 was selected. Derivation of a UL. The NOAEL of 11 mg/day was divided by a UF of 1.0 to obtain a UL of 11 mg/day of total manganese intake from food, water, and supplements for an adult.
MANGANESE 413 UL = NOAEL = 11 mg/day = 11 mg/day UF 1.0 Manganese UL Summary, Ages 19 Years and Older UL for Adults â¥ 19 years 11 mg/day of manganese Other Life Stage Groups Infants. For infants, the UL was judged not determinable because of lack of data on adverse effects in this age group and concern about the infantâs ability to handle excess amounts. To prevent high levels of manganese intake, the only source of intake for infants should be from food or formula. Children and Adolescents. There are no reports of manganese toxic- ity in children and adolescents. Given the dearth of information, the UL values for children and adolescents are extrapolated from those established for adults. Thus, the adult UL of 11 mg/day was adjusted on the basis of relative body weight as described in Chap- ter 2 using reference weights from Chapter 1 (Table 1-1). Pregnancy and Lactation. There are no data showing increased sus- ceptibility of pregnant or lactating women to manganese intake. Therefore, the ULs for pregnant and lactating women are the same as those for the nonpregnant and nonlactating women. Manganese UL Summary, Ages 0 through 18 Years, Pregnancy, Lactation UL for Infants 0â12 months Not possible to establish; source of intake should be from food and formula only UL for Children 1â3 years 2 mg/day of manganese 4â8 years 3 mg/day of manganese 9â13 years 6 mg/day of manganese UL for Adolescents 14â18 years 9 mg/day of manganese
414 DIETARY REFERENCE INTAKES UL for Pregnancy 14â18 years 9 mg/day of manganese 19â50 years 11 mg/day of manganese UL for Lactation 14â18 years 9 mg/day of manganese 19â50 years 11 mg/day of manganese Special Considerations Because manganese in drinking water and supplements may be more bioavailable than manganese from food, caution should be taken when using manganese supplements, especially among those persons already consuming large amounts of manganese from diets high in plant products. In addition, a review of the literature re- vealed that individuals with liver disease may be distinctly suscepti- ble to the adverse effects of excess manganese intake. Intake Assessment Based on the Total Diet Study (Appendix Table E-6), the highest dietary manganese intake at the ninety-fifth percentile was 6.3 mg/ day, which was the level consumed by men aged 31 to 50 years. Data from the Third National Health and Nutrition Examination Survey indicate that the highest supplemental intake of manganese at the ninety-fifth percentile was approximately 5 mg/day, which was con- sumed by men and women aged 19 years and older and pregnant women (Appendix Table C-20). Risk Characterization The risk of an adverse effect resulting from excess intake of man- ganese from food and supplements appears to be low at the highest intakes noted above. RESEARCH RECOMMENDATIONS FOR MANGANESE â¢ Identification of functional indicators for manganese. â¢ Analysis of effects of graded levels of dietary manganese intake on leukocyte superoxide dismutase activity or another appropriate functional indicator to provide an appropriate basis for setting an Estimated Average Requirement.
MANGANESE 415 REFERENCES Anderson RR. 1992. Comparison of trace elements in milk of four species. J Dairy Sci 75:3050â3055. Aquilio E, Spagnoli R, Seri S, Bottone G, Spennati G. 1996. Trace element content in human milk during lactation of preterm newborns. Biol Trace Elem Res 51:63â 70. Aschner M, Vrana KE, Zheng W. 1999. Manganese uptake and distribution in the central nervous system (CNS). Neurotoxicology 20:173â180. Barceloux DG. 1999. Manganese. J Toxicol Clin Toxicol 37:293â307. Behall KM, Scholfield DJ, Lee K, Powell AS, Moser PB. 1987. Mineral balance in adult men: Effect of four refined fibers. Am J Clin Nutr 46:307â314. Bell JG, Keen CL, Lonnerdal BJ. 1989. Higher retention of manganese in suckling than in adult rats is not due to maturational differences in manganese uptake by rat small intestine. J Toxicol Environ Health 26:387â398. Bonilla E. 1984. Chronic manganese intake induces changes in the motor activity of rats. Exp Neurol 84:696â700. Bonilla E, Prasad ALN. 1984. Effects of chronic manganese intake on the levels of biogenic amines in rat brain regions. Neurobehav Toxicol Teratol 6:341â344. Britton AA, Cotzias GC. 1966. Dependence of manganese turnover on intake. Am J Physiol 211:203â206. Brock AA, Chapman SA, Ulman EA, Wu G. 1994. Dietary manganese deficiency decreases rat hepatic arginase activity. J Nutr 124:340â344. Butterworth RF, Spahr L, Fontaine S, Layrargues GP. 1995. Manganese toxicity, dopaminergic dysfunction and hepatic encephalopathy. Metab Brain Dis 10:259â267. Carmichael S, Abrams B, Selvin S. 1997. The pattern of maternal weight gain in women with good pregnancy outcomes. Am J Public Health 87:1984â1988. Casey CE, Robinson MF. 1978. Copper, manganese, zinc, nickel, cadmium and lead in human foetal tissues. Br J Nutr 39:639â646. Casey CE, Hambidge KM, Neville MC. 1985. Studies in human lactation: Zinc, copper, manganese and chromium in human milk in the first month of lacta- tion. Am J Clin Nutr 41:1193â1200. Casey CE, Neville MC, Hambidge KM. 1989. Studies in human lactation: Secretion of zinc, copper, and manganese in human milk. Am J Clin Nutr 49:773â785. Cotzias GC, Miller ST, Papavasiliou PS, Tang LC. 1976. Interactions between man- ganese and brain dopamine. Med Clin North Am 60:729â738. Davidsson L, Cederblad A, Hagebo E, Lonnerdal B, Sandstrom B. 1988. Intrinsic and extrinsic labeling for studies of manganese absorption in humans. J Nutr 118:1517â1521. Davidsson L, Cederblad A, Lonnerdal B, Sandstrom B. 1989a. Manganese absorp- tion from human milk, cowâs milk, and infant formulas in humans. Am J Dis Child 143:823â827. Davidsson L, Cederblad A, Lonnerdal B, Sandstrom B. 1989b. Manganese reten- tion in man: A method for estimating manganese absorption in man. Am J Clin Nutr 49:170â179. Davidsson L, Lonnerdal B, Sandstrom B, Kunz C, Keen CL. 1989c. Identification of transferrin as the major plasma carrier protein for manganese introduced orally or intravenously or after in vitro addition in the rat. J Nutr 119:1461â 1464.
416 DIETARY REFERENCE INTAKES Davidsson L, Cederblad A, Lonnerdal B, Sandstrom B. 1991. The effect of individ- ual dietary components on manganese absorption in humans. Am J Clin Nutr 54:1065â1070. Davidsson L, Almgren A, Juillerat MA, Hurrell RF. 1995. Manganese absorption in humans: The effect of phytic acid and ascorbic acid in soy formula. Am J Clin Nutr 62:984â987. Davis CD, Greger JL. 1992. Longitudinal changes of manganese-dependent super- oxide dismutase and other indexes of manganese and iron status in women. Am J Clin Nutr 55:747â752. Davis CD, Ney DM, Greger JL. 1990. Manganese, iron and lipid interactions in rats. J Nutr 120:507â513. Davis CD, Wolf TL, Greger JL. 1992. Varying levels of manganese and iron affect absorption and gut endogenous losses of manganese by rats. J Nutr 122:1300â 1308. Davis CD, Zech L, Greger JL. 1993. Manganese metabolism in rats: An improved methodology for assessing gut endogenous losses. Proc Soc Exp Biol Med 202:103â108. Doisy EA Jr. 1973. Micronutrient controls on biosynthesis of clotting proteins and cholesterol. In: Hemphill DD, ed. Trace Substances in Environmental Health, VI. Columbia, MO: University of Missouri. Pp. 193â199. Dreosti IE, Manuel SJ, Buckley RA. 1982. Superoxide dismutase (EC 184.108.40.206), manganese and the effect of ethanol in adult and foetal rats. Br J Nutr 48:205â 210. Fechter LD. 1999. Distribution of manganese in development. Neurotoxicology 20:197â201. Finley JW. 1999. Manganese absorption and retention by young women is associat- ed with serum ferritin concentration. Am J Clin Nutr 70:37â43. Finley JW, Johnson PE, Johnson LK. 1994. Sex affects manganese absorption and retention by humans from a diet adequate in manganese. Am J Clin Nutr 60:949â955. Freeland-Graves J. 1994. Derivation of manganese estimated safe and adequate daily dietary intakes. In: Mertz W, Abernathy CO, Olin SS, eds. Risk Assessment of Essential Elements. Washington, DC: ILSI Press. Pp. 237â252. Freeland-Graves J, Lin PH. 1991. Plasma uptake of manganese as affected by oral loads of manganese, calcium, milk, phosphorous, copper and zinc. J Am Coll Nutr 10:38â43. Freeland-Graves J, Turnlund JR. 1996. Deliberations and evaluations of the ap- proaches, endpoints and paradigms for manganese and molybdenum dietary recommendations. J Nutr 126:2435Sâ2440S. Freeland-Graves J, Behmardi F, Bales CW, Dougherty V, Lin PH, Crosby JB, Trick- ett PC. 1988. Metabolic balance of manganese in young men consuming diets containing five levels of dietary manganese. J Nutr 118:764â773. Friedman BJ, Freeland-Graves JH, Bales CW, Behmardi F, Shorey-Kutschke RL, Willis RA, Crosby JB, Trickett PC, Houston SD. 1987. Manganese balance and clinical observations in young men fed a manganese-deficient diet. J Nutr 117:133â143. Garcia-Aranda JA, Wapnir RA, Lifshitz F. 1983. In vivo intestinal absorption of manganese in the rat. J Nutr 113:2601â2607. Gibson RS. 1994. Content and bioavailability of trace elements in vegetarian diets. Am J Clin Nutr 59:1223Sâ1232S.
MANGANESE 417 Gibson RS, De Wolfe MS. 1980. The dietary trace metal intake of some Canadian full-term and low birthweight infants during the first twelve months of infancy. J Can Diet Assoc 41:206â215. Greger JL. 1998. Dietary standards for manganese: Overlap between nutritional and toxicological studies. J Nutr 128:368Sâ371S. Greger JL. 1999. Nutrition versus toxicology of manganese in humans: Evaluation of potential biomarkers. Neurotoxicology 20:205â212. Greger JL, Baligar P, Abernathy RP, Bennett OA, Peterson T. 1978a. Calcium, magnesium, phosphorous, copper, and manganese balance in adolescent females. Am J Clin Nutr 31:117â121. Greger JL, Zaikis SC, Abernathy RP, Bennett OA, Huffman J. 1978b. Zinc, nitro- gen, copper, iron, and manganese balance in adolescent females fed two levels of zinc. J Nutr 108:1449â1456. Greger JL, Davis CD, Suttie JW, Lyle BJ. 1990. Intake, serum concentrations, and urinary excretion of manganese by adult males. Am J Clin Nutr 51:457â461. Hallfrisch J, Powell A, Carafelli C, Reiser S, Prather ES. 1987. Mineral balances of men and women consuming high fiber diets with complex or simple carbohy- drate. J Nutr 117:48â55. Hauser RA, Zesiewicz TA, Rosemurgy AS, Martinez C, Olanow CW. 1994. Manga- nese intoxication and chronic liver failure. Ann Neurol 36:871â875. Holbrook JT, Smith JC Jr, Reiser S. 1989. Dietary fructose or starch: Effects on copper, zinc, iron, manganese, calcium, and magnesium balances in humans. Am J Clin Nutr 49:1290â1294. Hunt JR, Matthys LA, Johnson LK. 1998. Zinc absorption, mineral balance, and blood lipids in women consuming controlled lactoovovegetarian and omni- vorous diets for 8 weeks. Am J Clin Nutr 67:421â430. Hurley LS, Keen CL. 1987. Manganese. In: Mertz W, ed. Trace Elements in Human and Animal Nutrition, 5th ed. San Diego: Academic Press. Pp. 185â223. IOM (Institute of Medicine) 1990. Nutrition During Pregnancy. Washington, DC: National Academy Press. Ivaturi R, Kies C. 1992. Mineral balances in humans as affected by fructose, high fructose corn syrup and sucrose. Plant Foods Hum Nutr 42:143â151. Johnson MA, Baier MJ, Greger JL. 1982. Effects of dietary tin on zinc, copper, iron, manganese, and magnesium metabolism of adult males. Am J Clin Nutr 35:1332â1338. Johnson P, Lykken G. 1991. Manganese and calcium absorption and balance in young women fed diets with varying amounts of manganese and calcium. J Trace Elem Exp Med 4:19â35. Johnson PE, Lykken GI, Korynta ED. 1991. Absorption and biological half-life in humans of intrinsic and extrinsic 54Mn tracers from foods of plant origin. J Nutr 121:711â717. Kawamura R, Ikuta H, Fukuzumi S, Yamada R, Tsubaki S, Kodama T, Kurata S. 1941. Intoxication by manganese in well water. Kitasato Arch Exp Med 18:145â 169. Keen CL, Zidenberg-Cherr S, Lonnerdal B. 1994. Nutritional and toxicological aspects of manganese intake: An overview. In: Mertz W, Abernathy CO, Olin SS, eds. Risk Assessment of Essential Elements. Washington, DC: ILSI Press. Pp. 221â235. Keen CL, Ensunsa JL, Watson MH, Baly DL, Donovan SM, Monaco MH, Clegg MS. 1999. Nutritional aspects of manganese from experimental studies. Neuro- toxicology 20:213â223.
418 DIETARY REFERENCE INTAKES Kelly DA. 1998. Liver complications of pediatric parenteral nutritionâepidemiology. Nutrition 14:153â157. Komura J, Sakamoto M. 1992. Effects of manganese forms on biogenic amines in the brain and behavioral alterations in the mouse: Long-term oral administra- tion of several manganese compounds. Environ Res 57:34â44. Kondakis XG, Makris N, Leotsinidis M, Prinou M, Papapetropoulos T. 1989. Possi- ble health effects of high manganese concentration in drinking water. Arch Environ Health 44:175â178. Krishna G, Whitlock HW Jr, Feldbruegge DH, Porter JW. 1966. Enzymatic conver- sion of farnesyl pyrophosphate to squalene. Arch Biochem Biophys 114: 200â215. Lonnerdal B, Keen CL, Hurley LS. 1981. Iron, copper, zinc and manganese in milk. Ann Rev Nutr 1:149â174. Lutz TA, Schroff A, Scharrer E. 1993. Effects of calcium and sugars on intestinal manganese absorption. Biol Trace Elem Res 39:221â227. Malecki EA, Huttner DL, Greger JL. 1994. Manganese status, gut endogenous losses of manganese, and antioxidant enzyme activity in rats fed varying levels of manganese and fat. Biol Trace Elem Res 42:17â29. McLeod BE, Robinson MF. 1972. Metabolic balance of manganese in young women. Br J Nutr 27:221â227. Morris SM Jr. 1992. Regulation of enzymes of urea and arginine synthesis. Ann Rev Nutr 12:81â101. Moss AJ, Levy AS, Kim I, Park YK. 1989. Use of Vitamin and Mineral Supplements in the United States: Current Users, Types of Products, and Nutrients. Advance Data, Vital and Health Statistics of the National Center for Health Statistics, Number 174. Hyattsville, MD: National Center for Health Statistics. Murthy GK. 1974. Trace elements in milk. Crit Rev Environ Control 4:1â38. Newland MC. 1999. Animal models of manganeseâs neurotoxicity. Neurotoxicology 20:415â432. Pappas BA, Zhang D, Davidson CM, Crowder T, Park GAS, Fortin T. 1997. Perinatal manganese exposure: Behavioral, neurochemical, and histopathological effects in the rat. Neurotoxicol Teratol 19:17â25. Patterson KY, Holbrook JT, Bodner JE, Kelsay JL, Smith JC Jr, Veillon C. 1984. Zinc, copper, and manganese intake and balance for adults consuming self- selected diets. Am J Clin Nutr 40:1397â1403. Paynter DI. 1980. Changes in activity of the manganese superoxide dismutase en- zyme in tissues of the rat with changes in dietary manganese. J Nutr 110:437â 447. Penland JG, Johnson PE. 1993. Dietary calcium and manganese effects on men- strual cycle symptoms. Am J Obstet Gynecol 168:1417â1423. Pennington JA, Young BE. 1991. Total Diet Study nutritional elements, 1982â1989. J Am Diet Assoc 91:179â183. Rabin O, Hegedus L, Bourre JM, Smith QR. 1993. Rapid brain uptake of manga- nese (II) across the blood-brain barrier. J Neurochem 61:509â517. Rossander-Hulten L, Brune M, Sandstrom B, Lonnerdal B, Hallberg L. 1991. Com- petitive inhibition of iron absorption by manganese and zinc in humans. Am J Clin Nutr 54:152â156. Sandstrom B, Davidsson L, Cederblad A, Eriksson R, Lonnerdal B. 1986. Manga- nese absorption and metabolism in man. Acta Pharmacol Toxicol 59:60â62.
MANGANESE 419 Sandstrom B, Davidsson L, Eriksson R, Alpsten M, Bogentoft C. 1987. Retention of selenium (75Se), Zinc (65Zn) and manganese (54Mn) in humans after intake of a labelled vitamin and mineral supplement. J Trace Elem Electrolytes Health Dis 1:33â38. Sandstrom B, Davidsson L, Erickson RA, Alpsten M. 1990. Effects of long-term trace element supplementation on blood trace element levels and absorption of (75Se), (54Mn), and (65Zn). J Trace Elem Electrolytes Health Dis 4:65â72. Schroeder HA, Balassa JJ, Tipton IH. 1966. Essential trace metals in man: Manga- nese. A study in homeostasis. J Chron Dis 19:545â571. Senturk UK, Oner G. 1996. The effect of manganese-induced hypercholesterolemia on learning in rats. Biol Trace Elem Res 51:249â257. Spahr L, Butterworth RF, Fontaine S, Bui L, Therrien G, Milette PC, Lebrun LH, Zayed J, LeBlanc A, Pomier-Layrargues G. 1996. Increased blood manganese in cirrhotic patients: Relationship to pallidal magnetic resonance signal hyper- intensity and neurological symptoms. Hepatology 24:1116â1120. Spencer H, Asmussen CR, Holtzman RB, Kramer L. 1979. Metabolic balances of cadmium, copper, manganese, and zinc in man. Am J Clin Nutr 32:1867â1875. Stastny D, Vogel RS, Picciano MF. 1984. Manganese intake and serum manganese concentration of human milk-fed and formula-fed infants. Am J Clin Nutr 39:872â878. Strause L, Saltman P. 1987. Role of manganese in bone metabolism. In: Kies C, ed. Nutritional Bioavailability of Manganese. Washington, DC: American Chemical Society. Pp. 46â55. Strause L, Hegenauer J, Saltman P, Cone R, Resnick D. 1986. Effects of long-term dietary manganese and copper deficiency on rat skeleton. J Nutr 116:135â141. Strause L, Saltman P, Glowacki J. 1987. The effect of deficiencies of manganese and copper on osteoinduction and on resorption of bone particles in rats. Calcif Tissue Int 41:145â150. Velazquez SF, Du JT. 1994. Derivation of the reference dose for manganese. In: Mertz W, Abernathy CO, Olin SS, eds. Risk Assessment of Essential Elements. Washington, DC: ILSI Press. Pp. 253â266. Vieregge P, Heinzow B, Korf G, Teichert HM, Schleifenbaum P, Mosinger HU. 1995. Long term exposure to manganese in rural well water has no neurolog- ical effects. Can J Neurol Sci 22:286â289. Zidenberg-Cherr S, Keen CL, Lonnerdal B, Hurley LS. 1983. Superoxide dismu- tase activity and lipid peroxidation in the rat: Developmental correlations af- fected by manganese deficiency. J Nutr 113:2498â2504.